U.S. Markets closed
  • S&P 500

    3,629.65
    -5.76 (-0.16%)
     
  • Dow 30

    29,872.47
    -173.77 (-0.58%)
     
  • Nasdaq

    12,094.40
    +57.62 (+0.48%)
     
  • Russell 2000

    1,845.02
    -8.51 (-0.46%)
     
  • Crude Oil

    45.32
    -0.39 (-0.85%)
     
  • Gold

    1,815.30
    +9.80 (+0.54%)
     
  • Silver

    23.48
    +0.11 (+0.48%)
     
  • EUR/USD

    1.1933
    +0.0014 (+0.1193%)
     
  • 10-Yr Bond

    0.8780
    -0.0040 (-0.45%)
     
  • Vix

    21.25
    -0.39 (-1.80%)
     
  • GBP/USD

    1.3371
    -0.0012 (-0.0896%)
     
  • USD/JPY

    104.2810
    -0.1590 (-0.1522%)
     
  • BTC-USD

    17,349.12
    -630.05 (-3.50%)
     
  • CMC Crypto 200

    337.76
    -32.76 (-8.84%)
     
  • FTSE 100

    6,384.96
    -6.13 (-0.10%)
     
  • Nikkei 225

    26,537.31
    +240.45 (+0.91%)
     

Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Pieris Pharmaceuticals, Inc. (PIRS) Investigation

·2 min read

NEW YORK, NY / ACCESSWIRE / July 22, 2020 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Pieris Pharmaceuticals, Inc. ("Pieris" or the "Company") (NASDAQ:PIRS).Investors who purchased Pieris securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: www.bgandg.com/pirs.

The investigation concerns whether Pieris and certain of its officers and/or directors have violated federal securities laws.

On July 20, 2020, Pieris announced that the U.S. Food and Drug Administration ("FDA" or the "Agency") had placed a partial clinical hold on the Company's Phase 1 studies of its PRS-343 product "while Pieris conducts an additional in-use and compatibility study requested by the Agency." Pieris specifically stated that "[t]he partial hold follows discussions with FDA regarding the Company's in-use study supporting the technical setup for clinical administration of PRS-343" and that the "FDA has requested that Pieris conduct an additional in-use and compatibility study of PRS-343 with various infusion materials under specific conditions to confirm suitability of PRS-343 for administration in clinical settings." On this news, Pieris's stock price fell sharply during intraday trading on July 21, 2010, damaging investors.

If you are aware of any facts relating to this investigation, or purchased Pieris shares, you can assist this investigation by visiting the firm's site: www.bgandg.com/pirs. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz and Grossman, LLC



View source version on accesswire.com:
https://www.accesswire.com/598411/Bronstein-Gewirtz-Grossman-LLC-Notifies-Investors-of-Pieris-Pharmaceuticals-Inc-PIRS-Investigation